ALZN logo

Alzamend Neuro Inc

ALZN
Healthcare|Biotechnology|US
$1.41
-0.14 (-9.03%)
Tangible Book / Share
$1.30
Cash / Share
$1.70

About

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Stock Price

-44.0%(1Y)
1M
+5.2%
3M
+2.9%
6M
+31.8%
YTD
-22.5%
1Y
-40.3%
3Y
-99.0%
5Y
-100.0%

Pipeline Summary

4 total trials
4
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
Active: 1Completed: 2Recruiting: 1

Active Trials (2)

Study in Subjects With Mild-to-Moderate Alzheimer's Dementia
NCT05834296Alzheimer Disease
Phase 1Phase 2Active
Enrollment: 30 participants
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder
NCT07540338Bipolar I Disorder
Phase 1Phase 2Recruiting
Enrollment: 20 participants

Key Facts

Market Cap$6.8M
Employees4 (+0% YoY)
CEOStephan Jackman
IPO DateJun 15, 2021
Beta0.19
52-Week Range$0.84 – $2.56
Avg Volume78,576
ExchangeNASDAQ
Websitealzamend.com

Ownership

Float99.8%
Shares Outstanding4.8M

Recent Insider Trades

AULT MILTON C IIISELL
Aug 26, 20262,000 shares @ $1.56
AULT MILTON C IIIBUY
Apr 14, 20262,000 shares @ $1.03
AULT MILTON C IIIBUY
Apr 14, 2026108,388 shares @ $1.00
AULT MILTON C IIIBUY
Apr 14, 20262,000 shares @ $1.03
Hyperscale Data, Inc.AWARD
Jul 31, 20267,500 shares

Peers

ACXPAcurx Pharmaceuticals, Inc.
$5.9M
ADILAdial Pharmaceuticals, Inc.
$13.3M
APREAprea Therapeutics, Inc.
$6.5M
BCDABioCardia, Inc.
$12.9M
CDIOCardio Diagnostics Holdings, Inc.
$4.9M
CELZCreative Medical Technology Holdings, Inc.
$1.6M
HCWBHCW Biologics Inc.
$354.6K
KPRXKiora Pharmaceuticals, Inc.
$6.4M

Recent News

Alzamend Neuro (ALZN) Upgraded to Buy: What Does It Mean for the Stock?
Oct 8, 2026 · zacks.com
Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
Aug 20, 2026 · prnewswire.com
Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain
Aug 18, 2026 · prnewswire.com
Data last updated: Nov 9, 2026, 03:54 AM